Skip to main content
Fig. 4 | Diagnostic Pathology

Fig. 4

From: Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Fig. 4

ROC analysis on confirmed objective response (per RECIST v1.1 per investigator). Analysis provided the rationale for the choice of tumor membrane score and 25 % cut-off. AUC area under the curve, NSCLC non-small cell lung cancer, RECIST Response Evaluation Criteria In Solid Tumors, ROC receiver operating characteristic, TM tumor membrane

Back to article page

Diagnostic Pathology

ISSN: 1746-1596

Contact us